Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Krystexxa: Big Expectations For An Orphan Market

Executive Summary

Savient's Krystexxa, an orphan drug candidate for treatment-failure gout, could bring in $600 million or more in worldwide sales by 2015, considerably bumping up the firm's potential value and making it pretty enough for picking as a potential acquisition candidate - or at the very least a collaboration partner

You may also be interested in...



Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains

After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.

Savient's Gout Therapy Krystexxa Delayed At FDA.

Manufacturing fixes should be straightforward - but the REMS submission could be tricky.

Savient's Gout Therapy Krystexxa Delayed At FDA

The biggest delay in Savient's resubmission of its gout therapy Krystexxa (pegloticase) could come from FDA's request that the sponsor include detailed materials for its Risk Evaluation and Mitigation Strategy as part of the resubmission

Related Content

Topics

UsernamePublicRestriction

Register

PS051196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel